EVOPACS试验:依洛尤单抗用于急性冠脉综合征早期降低LDL-C
EVOPACS是一项随机双盲安慰剂对照试验,纳入308例急性冠脉综合征住院且LDL-C升高的患者,在阿托伐他汀40mg基础上随机加用依洛尤单抗420mg或安慰剂。主要终点为8周LDL-C计算值百分比变化,依洛尤单抗组较安慰剂组多降低40.7%(95%CI -45.2至-36.2,P<0.001),且耐受性良好。
要点
- ACS住院期启动依洛尤单抗420mg可显著降低LDL-C,8周降幅额外达40.7%。
- 依洛尤单抗组95.7%患者8周LDL-C达标<1.8mmol/L,安慰剂组为37.6%。
- 不良事件与中心裁定心血管事件两组相似,未观察到新的安全性信号。
核心结论
- 在ACS急性期于高强度他汀基础上加用依洛尤单抗耐受性良好,可大幅降低LDL-C,使超过95%患者达到当前推荐目标水平。
研究设计与样本
- 研究者发起的随机双盲安慰剂对照试验,纳入308例因ACS住院且LDL-C升高的患者,1:1随机接受皮下依洛尤单抗420mg或安慰剂,住院期及4周后给药,背景为阿托伐他汀40mg。
主要发现
- 主要终点为基线至8周计算LDL-C百分比变化,依洛尤单抗组较安慰剂组差异为-40.7%(95%CI -45.2至-36.2,P<0.001)。
- 依洛尤单抗组平均LDL-C从3.61降至0.79mmol/L,安慰剂组从3.42降至2.06mmol/L。
- 8周时LDL-C<1.8mmol/L者依洛尤单抗组占95.7%,安慰剂组占37.6%。
- 不良事件及中心裁定的心血管事件两组相似。
关键数值与推荐
- 入选LDL-C标准:高强度他汀至少4周者≥1.8mmol/L;低或中等强度他汀者≥2.3mmol/L;无稳定他汀剂量者≥3.2mmol/L。
- 78.2%患者既往未接受他汀治疗。
临床怎么用
- ACS住院期可考虑在阿托伐他汀40mg基础上早期加用依洛尤单抗420mg,以快速实现LDL-C达标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly acting, potent LDL-C-lowering drug, has not been studied in the acute phase of ACS. OBJECTIVES: The purpose of this study was to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab initiated during the in-hospital phase of ACS. METHODS: The authors conducted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 patients hospitalized for ACS with elevated LDL-C levels (≥1.8 mmol/l on high-intensity statin for at least 4 weeks; ≥2.3 mmol/l on low- or moderate-intensity statin; or ≥3.2 mmol/l on no stable dose of statin). Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg. The primary endpoint was percentage change in calculated LDL-C from baseline to 8 weeks. RESULTS: Most patients (78.2%) had not been on previous statin treatment. Mean LDL-C levels decreased from 3.61 to 0.79 mmol/l at week 8 in the evolocumab group, and from 3.42 to 2.06 mmol/l in the placebo group; the difference in mean percentage change from baseline was -40.7% (95% confidence interval: -45.2 to -36.2; p < 0.001). LDL-C levels <1.8 mmol/l were achieved at week 8 by 95.7% of patients in the evolocumab group versus 37.6% in the placebo group. Adverse events and centrally adjudicated cardiovascular events were similar in both groups. CONCLUSIONS: In this first randomized trial assessing a PCSK9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently recommended target levels. (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes [EVOPACS]; NCT03287609).
引用
- Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019. PMID: 31479722. doi:10.1016/j.jacc.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。